Pharmaceuticals

Pliant Therapeutics

RBC Capital Analyst Maintains 'Hold' Rating on Pliant Therapeutics

Pliant Therapeutics released FY2025 9 Months earnings on November 6 (EST), actual revenue USD 0, actual EPS USD -2.051

Pliant Therapeutics released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4299 (forecast USD -0.5233)

Pliant Therapeutics released FY2025 Semi-Annual Earnings on August 7 (EST), actual revenue USD 0, actual EPS USD -1.6224

Pliant Therapeutics released FY2025 Q2 earnings on August 7, 2025 (EST), with actual revenue USD 0 (forecast USD 0) and actual EPS USD -0.7053 (forecast USD -0.7338)

Pliant Therapeutics updates BEACON-IPF trial

Pliant Therapeutics Stops IPF Drug Development

Pliant Implements Cost-Cutting Measures to Support Late-Stage Clinical Trials

Pliant Cutting Costs to Prepare for Later-Stage Clinical Trials

Pliant cuts costs to advance late-stage clinical trials

Pliant Implements Cost Reduction Strategies

Pliant Therapeutics Displays Bexotegrast Data and Receives FDA, EMA Approvals

Pliant Implements Cost Cutting Measures

Pliant Implements Cost-Cutting Measures for Advancing Clinical Trials

Pliant Implements Cost-saving Measures for Late-stage Clinical Trials

Pliant Implements Cost-Cutting Strategies for Late-Stage Clinical Trials

Pliant Tightens Cost Cutting Measures for Advanced Clinical Trials

Pliant Therapeutics released FY2025 Q1 earnings on May 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.9174 (forecast USD -0.7354)

Pliant Therapeutics Reports Increased Q1 2025 Loss and Announces Strategic Restructuring

Pliant Therapeutics Inc reports Q1 EPS loss of 72 cents

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap